Literature DB >> 11135275

Gastrointestinal carcinoid tumors and second primary malignancies.

N Habal1, C Sims, A J Bilchik.   

Abstract

The development of second primary malignancies (SPM) in patients with gastrointestinal carcinoid tumors is a well-described phenomenon, with reported rates as high as 55%. There is a predilection for gastrointestinal and genitourinary adenocarcinomas, but a variety of other malignancies have been reported as well. The etiology of this malignant predisposition may be rooted in the tumorigenic properties of the various neuroendocrine peptides elaborated and secreted by neuroendocrine cells. Peptides such as secretin, gastrin, bombesin, cholecystokinin (CCK), and vasoactive intestinal peptide (VIP) are believed to promote the growth of tumor cells. As many as 30 peptides and amines identified in neuroendocrine cells may have similar properties. This review of the literature on carcinoid-associated second primary malignancies is accompanied by a case report of metastatic carcinoid identified during surgical exploration for a perforating colon adenocarcinoma. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11135275     DOI: 10.1002/1096-9098(200012)75:4<306::aid-jso14>3.0.co;2-3

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  41 in total

1.  Four tumours including neuroendocrine tumour of the ileum.

Authors:  Karen Waldon; Jonathan Raihan Abbas; Savana Shakir; Samir Afify
Journal:  BMJ Case Rep       Date:  2015-05-02

Review 2.  Neuroendocrine tumors of the gastro-entero-pancreatic system.

Authors:  Sara Massironi; Valentina Sciola; Maddalena Peracchi; Clorinda Ciafardini; Matilde Pia Spampatti; Dario Conte
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

3.  Diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors: current data on a prospectively collected, retrospectively analyzed clinical multicenter investigation.

Authors:  Martin B Niederle; Bruno Niederle
Journal:  Oncologist       Date:  2011-04-05

4.  Synchronous collision neuroendocrine tumor and rectal adenocarcinoma: a case report.

Authors:  Jie-Gao Zhu; Zhong-Tao Zhang; Guo-Cong Wu; Wei Han; Kang-Li Wang
Journal:  Indian J Surg       Date:  2015-03-11       Impact factor: 0.656

Review 5.  Synchronous double cancers of colonic large cell neuroendocrine carcinoma and gastric squamous-cell carcinoma: a case report and review of literature.

Authors:  Feng Xu; Guo-Sheng Feng; Zhen-Jun Wang; Kun-Ning Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

Review 6.  Pathologic research update of colorectal neuroendocrine tumors.

Authors:  Shu-Juan Ni; Wei-Qi Sheng; Xiang Du
Journal:  World J Gastroenterol       Date:  2010-04-14       Impact factor: 5.742

7.  Role of Staging in Patients with Small Intestinal Neuroendocrine Tumours.

Authors:  Ashley Kieran Clift; Omar Faiz; Adil Al-Nahhas; Andreas Bockisch; Marc Olaf Liedke; Erik Schloericke; Harpreet Wasan; John Martin; Paul Ziprin; Krishna Moorthy; Andrea Frilling
Journal:  J Gastrointest Surg       Date:  2015-09-22       Impact factor: 3.452

8.  Three synchronous gastrointestinal tumours.

Authors:  B M Boland; C G Collins; E Christiansen; A O'Brien; J Duignan
Journal:  Ir J Med Sci       Date:  2009-03-17       Impact factor: 1.568

9.  Gastroenteropancreatic neuroendocrine tumors: 10-year experience in a single center.

Authors:  Ozcan Yildiz; Mustafa Ozguroglu; Teoman Yanmaz; Hande Turna; Suheyla Serdengecti; Gulen Dogusoy
Journal:  Med Oncol       Date:  2009-11-03       Impact factor: 3.064

10.  Long-Term Survival is not Impaired After the Complete Resection of Neuroendocrine Tumors of the Appendix.

Authors:  Thomas Steffen; Sabrina M Ebinger; René Warschkow; Cornelia Lüthi; Bruno M Schmied; Thomas Clerici
Journal:  World J Surg       Date:  2015-11       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.